21 completed. 21 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 21 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Efinopegdutide, Placebo - Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 85 | 2024-07-12 | 2026-09-21 |
| A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH DD01, Placebo - NAFLD, NASH | Phase 2 | Completed | Neuraly, Inc. | 67 | 2024-06-13 | 2026-05-01 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
| A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Efinopegdutide, Semaglutide, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2023-06-23 | 2026-01-12 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-11-04 |
| Ketohexokinase Inhibition in NAFLD Ketohexokinase inhibition, Placebo - NAFLD | Phase 2 | Completed | Maastricht University Medical Center | 15 | 2022-10-01 | 2024-01-24 |
| The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease LUM-201 - NAFLD, Nonalcoholic Fatty Liver | Phase 2 | Completed | Massachusetts General Hospital | 12 | 2022-08-10 | 2026-01-06 |
| Different Doses of ZED1227 vs. Placebo in NAFLD ZED1227, Placebo - NAFLD, Liver Fibrosis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 186 | 2022-04-19 | 2024-05-14 |
| Vigabatrin and Insulin Sensitivity Vigabatrin - NAFLD, Obesity | Phase 2 | Completed | Washington University School of Medicine | 4 | 2021-08-23 | 2025-01-14 |
| Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) Tocotrienols / Vitamin E, Placebo control - Hepatic Steatosis, NAFLD | Phase 2 | Completed | Yuen Kah Hay | 170 | 2021-01-01 | 2024-05-10 |
| A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Elobixibat, Placebo oral tablet - NAFLD, NASH | Phase 2 | Completed | Albireo | 47 | 2019-06-06 | 2026-02-05 |
| Treating PCOS With Semaglutide vs Active Lifestyle Intervention Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet - PCOS, Adolescent Obesity | Phase 2 / Phase 3 | Completed | University of Colorado, Denver | 60 | 2019-05-03 | 2025-11-25 |
| Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) Saroglitazar - Liver Transplant; Complications, NAFLD | Phase 2 | Completed | Zydus Therapeutics Inc. | 20 | 2019-02-25 | 2024-10-24 |
| A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) HTD1801, Placebo - Fatty Liver, Nonalcoholic, NAFLD | Phase 2 | Completed | HighTide Therapeutics (Hong Kong) Limited | 101 | 2018-11-26 | 2026-08-25 |
| Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg - NAFLD, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Akcea Therapeutics | 105 | 2017-12-21 | 2021-02-01 |
| Treatment of NAFLD With Two Different Diets 5:2 diet, LCHF, Placebo diet - NAFLD | Phase 2 | Completed | Karolinska University Hospital | 74 | 2017-04-06 | 2020-09-02 |
| Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease VK2809, Placebo - Hyperlipidemia, NAFLD | Phase 2 | Completed | Viking Therapeutics, Inc. | 59 | 2016-09-28 | 2021-04-26 |
| The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo - NAFLD | Phase 2 | Completed | NuSirt Biopharma | 91 | 2015-11-19 | 2018-05-02 |
| CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis | Phase 2 | Completed | University of Michigan | 11 | 2015-09-29 | 2020-11-24 |
| Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents Resveratrol, Placebo - NAFLD, TYPE 2 DIABETES | Phase 2 / Phase 3 | Completed | University of Manitoba | 10 | 2015-08-01 | 2017-05-05 |
Showing 20 of 21. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (21) · Fatty Liver (4) · Diabetes Mellitus, Type 2 (3) · Obesity (3) · Digestive System Diseases (2) · Insulin Resistance (2) · Liver Cirrhosis (2) · Liver Diseases (2) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperlipidemias (1) · Hypertriglyceridemia (1) · Lipodystrophy, Familial Partial (1) · Metabolic Diseases (1)
Digestive System Diseases (19) · Liver Diseases (19) · Fatty Liver (17) · Nutritional and Metabolic Diseases (9) · Metabolic Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Body Weight (4) · Glucose Metabolism Disorders (4) · Nutrition Disorders (4) · Overnutrition (4) · Overweight (4) · Signs and Symptoms (4) · Hyperinsulinism (3) · Lipid Metabolism Disorders (3) · Diabetes Mellitus (2)
semaglutide (2) · 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane (1) · Dasatinib (1) · Diet (1) · Diet, Reducing (1) · Glucagon (1) · IONIS-ANGPTL3-LRx (1) · Losartan (1) · Quercetin (1) · Resveratrol (1) · Tocotrienols (1) · Vigabatrin (1) · Vitamin E (1) · ZED1227 (1) · elobixibat (1)
Merck Sharp & Dohme LLC (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Adrian Vella (1) · Akcea Therapeutics (1) · Albireo (1) · Dr. Falk Pharma GmbH (1) · HighTide Therapeutics (Hong Kong) Limited (1) · Karolinska University Hospital (1) · Maastricht University Medical Center (1) · Massachusetts General Hospital (1) · Miriam Vos, MD (1) · Neuraly, Inc. (1) · NuSirt Biopharma (1) · University of Colorado, Denver (1) · University of Manitoba (1)
United States (15) · Canada (4) · Colombia (2) · France (2) · Israel (2) · Japan (2) · Netherlands (2) · Puerto Rico (2) · Spain (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Chile (1)
Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Adrian Vella (1) · Brandy A Wicklow, MD, MSc (1) · Dennis To (1) · Deven Parmar, MD FCP (1) · Elif A Oral, MD (1) · Kah Hay Yuen, PhD (1) · Laura E. Dichtel, MD, MHS (1) · Marianne Mancini (1) · Max Nieuwdorp, MD, PhD (1) · Melanie Cree-Green, MD, PhD (1) · Miriam Vos, MD, MSPH (1) · Orville Kolterman, MD (1)
PMID 29992039, PMID 30569637, PMID 33898960, PMID 34535644, PMID 36318027, PMID 36847136, PMID 40797298, PMID 42014131, PMID 42480572, PMID 42823536, PMID 42844400
R01DK116231 (1), R01DK120612 (1), R03DK096157 (1)